First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline

March 14, 2024

https://www.globenewswire.com/news-release/2024/03/14/2846098/0/en/First-Wave-BioPharma-Announces-Completion-of-Business-Combination-with-ImmunogenX-Adding-Phase-3-Ready-Latiglutenase-to-its-Late-Stage-GI-Focused-Clinical-Pipeline.html

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease

James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma; Jack Syage, Ph.D., named President and Chief Operating Officer

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.